A Phase 2 interventional study of ALX-0061 and Placebo in Lupus Erythematosus, Systemic, sponsored by Ablynx, a Sanofi company. Completed at 118 sites in 17 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Ablynx, a Sanofi company · Phase 2, Interventional, and Treatment
Primary objective:
To assess the efficacy and safety of different dose regimens of ALX-0061 administered subcutaneously (s.c.) to subjects with moderate to severe active, seropositive systemic lupus erythematosus (SLE) compared to placebo.
Secondary objectives:
To assess the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, flare rate, steroid reduction and health-related quality of life, with different dose regimens of ALX-0061.
1,202 studies on the registry are indexed under Lupus Erythematosus, Systemic; 399 are open to participants now.
This study's enrollment of 312 is above the median of 50 across 867 interventional studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →Ablynx, a Sanofi company is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Two s.c. injections with placebo every 2 weeks (q2w). \*\*\* Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w: Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46. Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46.
Biological: Placebo
ALX-0061 75 mg every 4 weeks (q4w). \*\*\* Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w: Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46. Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.
Biological: ALX-0061 · Biological: Placebo
ALX-0061 150 mg every 4 weeks (q4w). \*\*\* Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w: Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46. Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46.
Biological: ALX-0061 · Biological: Placebo
ALX-0061 150 mg every 2 weeks (q2w). \*\*\* Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w: Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46. Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46.
Biological: ALX-0061 · Biological: Placebo
ALX-0061 225 mg every 2 weeks (q2w). \*\*\* Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w: Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46. Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46.
Biological: ALX-0061
Number and Percentage of Subjects Who Achieved a Response at Week 24 According to the Modified British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (mBICLA) Score
The primary endpoint was evaluated by determining if there was a dose-response relationship between the mBICLA response rate at Week 24 and the dose administered, using the Multiple Comparison Procedure - Modelling (MCP-Mod) methodology. The existence of several candidate parametric models was assumed and multiple comparison techniques were used to choose the model(s) most likely to represent the true underlying dose-response curve. The selected model could further be used to guide the choice of adequate doses. mBICLA responders were defined as subjects who met all of the following criteria: 1. BILAG-2004 normal improvement: all A scores at Baseline improved to B, C or D, and all B scores improved to C or D. 2. No worsening in disease activity: no new BILAG-2004 A scores and ≤ 1 new increase to B. 3. No worsening of total mSLEDAI-2K score from Baseline. 4. No significant deterioration (\< 10% worsening from Baseline) in PGA. 5. No treatment failure (including the premature
Time frame: At Week 24 visit
Number and Percentage of Subjects With mBICLA Response at Week 24 and Week 48
Number and percentage of mBICLA responders at Week 24 and Week 48
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With Modified Systemic Lupus Erythematosus Responder Index (mSRI-4) Response at Week 24 and Week 48
The composite index mSRI-4 enables quantification of decrease and increase in disease activity in a broad spectrum of manifestations thereby offering a comprehensive assessment of SLE disease status. mSRI combines advantages from 3 validated measurement tools. The mSRI-4 criteria for response are: 1. modified SLE disease activity index 2000 (mSLEDAI-2K): ≥ 4 point reduction (covers global disease improvement), 2. British Isles Lupus Assessment Group 2004 (BILAG-2004): no new A domain score and no more than 1 new increase to B (covers organ-specific disease improvement), 3. Physician's Global Assessment (PGA) (is used as validity and safety net for items that were not addressed by the other two indices): \< 10% increase from Baseline (no worsening) When all 3 criteria are met, the subject is a mSRI-4 responder at that time point. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With mSRI-5 Response at Week 24 and Week 48
The mSRI-5 criteria for response are: 1. mSLEDAI-2K: ≥ 5 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 5 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With mSRI-6 Response at Week 24 and Week 48
The mSRI-6 criteria for response are: 1. mSLEDAI-2K: ≥ 6 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 6 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With mSRI-7 Response at Week 24 and Week 48
The mSRI-7 criteria for response are: 1. mSLEDAI-2K: ≥ 7 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 7 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With mSRI-8 Response at Week 24 and Week 48.
The mSRI-8 criteria for response are: 1. mSLEDAI-2K: ≥ 8 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 8 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
Time frame: At Week 24 and Week 48
Change From Baseline in Modified Systemic Lupus Erythematosus Disease Activity Index 2000 (mSLEDAI-2K) Score at Week 24 and Week 48
The Systemic Lupus Erythematosus Disease Activity Index 2000 is a 1-page weighted score for 24 items (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, etc). The manifestations felt to be most commonly contributing to disease activity are included and scored based on the presence (= 1 multiplied by weight) or absence (= 0) within 30 days prior to the evaluation. The total score ranges from 0-105 (= sum of individual scores), with 105 being higher disease activity. mSLEDAI-2K derives from the standard index by omitting low complement. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline mSLEDAI-2K Score and geographic region as covariates. A negative change from baseline reflects an improvement.
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With BILAG-2004 Normal Improvement at Week 24 and Week 48
Normal Improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D. Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With BILAG-2004 Enhanced Improvement at Week 24 and Week 48
Enhanced improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D and no worsening between consecutive visits from baseline up to the considered visit Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
Time frame: At Week 24 and Week 48
BILAG-2004 Total Score at Baseline, Week 24 and Week 48
The British Isles Lupus Assessment Group 2004 (BILAG-2004) is a comprehensive composite clinical index that has been developed based on the principle of a physician's intention to treat using a nominal consensus approach. In the index, the nine systems (not organs) considered are: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, renal, ophthalmic and hematological. Disease activity in each of the nine systems is categorized into five levels: grades A (= severe disease activity requiring systemic high dose oral corticosteroids, i.v. pulse corticosteroids, etc.) to E (= system never involved). BILAG total score is derived by assigning the following value to each grade and summing the sores over all organ systems: A = 12, B = 8, C = 1, D/E = 0. The total score ranges from 0-108, with 108 representing high disease activity in all 9 systems requiring high doses of corticosteroids, starting/increasing immunosuppressive drugs, etc.
Time frame: At Baseline, Week 24 and Week 48
Number and Percentage of Subjects With BILAG-2004 Normal Improvement in Mucocutaneous System at Week 24 and Week 48
An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D. Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With BILAG-2004 Normal Improvement in Musculoskeletal System at Week 24 and Week 48
An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D. Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects With Persistent Minimal or no Activity in 9 Organ Systems According to BILAG-2004 Systems Tally at Week 24 and Week 48
Time frame: At Week 24 and Week 48
Change From Baseline in Physician's Global Assessment (PGA) at Week 24 and Week 48
The physician makes a mark between 0 ("no disease") and 100 mm ("severe disease") on the visual analogue scale (VAS) to indicate disease activity (independent of the subject's self-assessment). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline PGA score and geographic region as covariates. A negative change from baseline reflects an improvement.
Time frame: At Week 24 and Week 48
Change From Baseline in Patient's Global Assessment at Week 24 and Week 48
The subject makes a mark between 0 ("very good") and 100 mm ("very bad") on the VAS to indicate how the subject is doing, while considering all the ways SLE affects him/her. Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline Patient's Global Assessment and geographic region as covariates. A negative change from baseline reflects an improvement.
Time frame: At Week 24 and Week 48
Change From Baseline in Proteinuria at Week 24 and Week 48
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline proteinuria and geographic region as covariates
Time frame: At Week 24 and Week 48
Number of Subjects Who Were Treatment-emergent Urine Sediment Positive at Week 24 and Week 48
Efficacy Laboratory Parameters (Urinalysis) - Active Urine Sediment Number of subjects who were urine sediment negative at Baseline, but positive at Week 24 and Week 48, respectively.
Time frame: At Week 24 and Week 48
Change From Baseline in Serum Creatinine at Week 24 and Week 48
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline serum creatinine and geographic region as covariates
Time frame: At Week 24 and Week 48
Change From Baseline in Creatinine Clearance Estimation (eGFR) at Week 24 and Week 48
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline eGFR and geographic region as covariates
Time frame: At Week 24 and Week 48
Number of and Percentage Treatment Failures From Baseline to Week 24 and Week 48
Defined as non-protocol allowed increase in steroid dose, start i.v. or i.m. steroids, or start or increase of immunosuppressant
Time frame: From Baseline to Week 24 and Week 48
Number and Percentage of Subjects Experiencing Severe Flares According to BILAG-2004 Flare Index From Baseline to Week 24 and Week 48
Time frame: From Baseline to Week 24 and Week 48
Number and Percentage of Subjects Experiencing Severe Flares According to mSLEDAI-2K Flare Index (mSFI) From Baseline to Week 24 and Week 48
Time frame: From Baseline to Week 24 and Week 48
Percent Change From Baseline in Daily Dose of Steroids at Week 24 and Week 48
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline prednisone equivalent total daily dose and geographic region as covariates
Time frame: At Week 24 and Week 48
Number and Percentage of Subjects Whose Daily Dose of Steroids Was Reduced Without Severe Flares During Weeks 40-48
Number and percentage of subjects whose prednisone equivalent dose was \>7.5 mg/day at baseline and reduced to ≤7.5 mg/day during Weeks 40-48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare after the first prednisone equivalent dose decrease.
Time frame: Between Week 40 and Week 48
Number and Percentage of Subjects Who Discontinued Prednisone (or Equivalent) by Week 48 Without Experiencing a Severe Flare
Number and percentage of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare
Time frame: Up to and including Week 48
Change From Baseline in Physical Component Scores of Short Form (36) Health Survey (SF-36) at Week 24 and Week 48
The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement.
Time frame: At Week 24 and Week 48
Change From Baseline in Mental Component Scores of SF-36 at Week 24 and Week 48
The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement.
Time frame: At Week 24 and Week 48
Change From Baseline in 28 Joint Count Swollenness (SJC28) Score at Week 24 and Week 48
Twenty-eight joints are assessed for swollenness (a score of 1 for a joint denotes a presence of swollenness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are swollen). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SJC28 Score and geographic region as covariates. A negative change denotes an improvement.
Time frame: At Week 24 and Week 48
Change From Baseline in 28 Joint Count Tenderness (TJC28) Score at Week 24 and Week 48
Twenty-eight joints are assessed for tenderness (a score of 1 for a joint denotes a presence of tenderness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are tender). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline TJC28 Score and geographic region as covariates. A negative change denotes and improvement.
Time frame: At Week 24 and Week 48
Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12, Week 24 and Week 48
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (erythema: 0=absent, 1=pink, 2=red, 3=dark red; scale: 0=absent, 1=scale, 2=verrucous/hypertrophic). Mucous membrane involvement and acute hair loss are scored based on the presence (=1) or absence (=0). Nonscarring alopecia is scored as 0=absent, 1=diffuse/non-inflammatory, 2=focal or patchy in 1 quadrant, 3=focal or patchy in \>1 quadrant. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Activity Score and geographic region as covariates. Negative change = improvement
Time frame: At Week 12, Week 24 and Week 48
Change From Baseline in CLASI Damage Score at Week 12, Week 24 and Week 48
CLASI Damage is scored based on dyspigmentation and scarring. Evaluation of dyspigmentation and scarring is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (dyspigmentation: 0=absent, 1=present; scarring: 0=absent, 1=scarring, 2=severely atrophic scarring or panniculitis). Subjects are also asked whether dyspigmentation due to SLE lesions usually remains visible for \>12 months, which is considered permanent and results in doubling of the dyspigmentation score. Scarring alopecia is scored as follows: 0=absent, 3=1 quadrant, 4=2 quadrants, 5=3 quadrants, 6=affects the whole skull. Total score ranges from 0-56, with higher scores indicating more damaged skin. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Damage Score and geographic region as covariates. Negative change = improvement.
Time frame: At Week 12, Week 24 and Week 48
ALX-0061 Serum Concentrations at Week 24 and Week 48
Time frame: At Week 24 and Week 48
Actual Values of Soluble Interleukin 6 Receptor (sIL-6R) Concentrations at Baseline, Week 24, and Week 48
Time frame: At Baseline, Week 24, and Week 48
Actual Values of C-reactive Protein (CRP) Concentrations at Baseline, Week 24, and Week 48
Time frame: At Baseline, Week 24, and Week 48
Actual Values of Fibrinogen Concentrations at Baseline, Week 24, and Week 48
Time frame: At Baseline, Week 24, and Week 48
Actual Values of Anti-double-stranded (ds) DNA Concentrations at Baseline, Week 24, and Week 48
Time frame: at Baseline, Week 24, and Week 48
Actual Values of Complement C3 Concentrations at Baseline, Week 24, and Week 48
Time frame: At Baseline, Week 24, and Week 48
Actual Values of Complement C4 Concentrations at Baseline, Week 24, and Week 48
Time frame: At Baseline, Week 24, and Week 48
Actual Values for Hemolytic Complement Component 50 (CH50) at Baseline, Week 24, and Week 48
Time frame: At Baseline, Week 24, and Week 48
Number and Percentage of Subjects Who Were Treatment-emergent (TE) Anti-drug Antibody (ADA) Positive
Time frame: From first administration of ALX-0061 up to and including follow-up
A total of 312 subjects were randomized at 91 sites located in Europe (37 sites; 155 subjects), Asia-Pacific (19 sites, 53 subjects), North America (21 sites; 52 subjects), and Latin America (14 sites, 52 subjects). Consent was obtained from the first subject on 02 July 2015; the last subject completed the final visit on 25 January 2018.
| Milestone | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Started | 62 | 64 | 62 | 62 | 62 |
| Completed | 54 | 48 | 47 | 40 | 46 |
| Not completed | 8 | 16 | 15 | 22 | 16 |
| Withdrew: Non-compliance to study drug | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Sponsor's decision | 1 | 1 | 4 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Unable to attend visit(s) | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 | 3 | 1 |
| Withdrew: Adverse event | 4 | 9 | 5 | 11 | 7 |
| Withdrew: Withdrawal by subject | 1 | 2 | 6 | 5 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 2 | 0 |
The primary endpoint was evaluated by determining if there was a dose-response relationship between the mBICLA response rate at Week 24 and the dose administered, using the Multiple Comparison Procedure - Modelling (MCP-Mod) methodology. The existence of several candidate parametric models was assumed and multiple comparison techniques were used to choose the model(s) most likely to represent the true underlying dose-response curve. The selected model could further be used to guide the choice of adequate doses. mBICLA responders were defined as subjects who met all of the following criteria: 1. BILAG-2004 normal improvement: all A scores at Baseline improved to B, C or D, and all B scores improved to C or D. 2. No worsening in disease activity: no new BILAG-2004 A scores and ≤ 1 new increase to B. 3. No worsening of total mSLEDAI-2K score from Baseline. 4. No significant deterioration (\< 10% worsening from Baseline) in PGA. 5. No treatment failure (including the premature
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Number and Percentage of Subjects Who Achieved a Response at Week 24 According to the Modified British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (mBICLA) Score | 29 | 28 | 24 | 24 | 23 |
Number and percentage of mBICLA responders at Week 24 and Week 48
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 28 | 28 | 22 | 24 | 22 |
| Week 48 | 28 | 32 | 22 | 19 | 22 |
The composite index mSRI-4 enables quantification of decrease and increase in disease activity in a broad spectrum of manifestations thereby offering a comprehensive assessment of SLE disease status. mSRI combines advantages from 3 validated measurement tools. The mSRI-4 criteria for response are: 1. modified SLE disease activity index 2000 (mSLEDAI-2K): ≥ 4 point reduction (covers global disease improvement), 2. British Isles Lupus Assessment Group 2004 (BILAG-2004): no new A domain score and no more than 1 new increase to B (covers organ-specific disease improvement), 3. Physician's Global Assessment (PGA) (is used as validity and safety net for items that were not addressed by the other two indices): \< 10% increase from Baseline (no worsening) When all 3 criteria are met, the subject is a mSRI-4 responder at that time point. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 37 | 39 | 30 | 33 | 29 |
| Week 48 | 34 | 36 | 29 | 26 | 33 |
The mSRI-5 criteria for response are: 1. mSLEDAI-2K: ≥ 5 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 5 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 17 | 24 | 19 | 20 | 16 |
| Week 48 | 20 | 28 | 18 | 16 | 22 |
The mSRI-6 criteria for response are: 1. mSLEDAI-2K: ≥ 6 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 6 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 16 | 23 | 19 | 19 | 15 |
| Week 48 | 20 | 28 | 16 | 16 | 22 |
The mSRI-7 criteria for response are: 1. mSLEDAI-2K: ≥ 7 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 7 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 9 | 8 | 8 | 12 | 7 |
| Week 48 | 12 | 14 | 7 | 8 | 9 |
The mSRI-8 criteria for response are: 1. mSLEDAI-2K: ≥ 8 point reduction 2. BILAG-2004: no new A domain score and no more than 1 new increase to B domain score 3. PGA: no worsening (\< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 8 were considered for the derivation of that endpoint. Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation.
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 9 | 7 | 8 | 10 | 7 |
| Week 48 | 11 | 14 | 7 | 7 | 8 |
The Systemic Lupus Erythematosus Disease Activity Index 2000 is a 1-page weighted score for 24 items (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, etc). The manifestations felt to be most commonly contributing to disease activity are included and scored based on the presence (= 1 multiplied by weight) or absence (= 0) within 30 days prior to the evaluation. The total score ranges from 0-105 (= sum of individual scores), with 105 being higher disease activity. mSLEDAI-2K derives from the standard index by omitting low complement. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline mSLEDAI-2K Score and geographic region as covariates. A negative change from baseline reflects an improvement.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -4.0 ± 0.42 | -4.6 ± 0.43 | -3.8 ± 0.43 | -4.3 ± 0.44 | -3.6 ± 0.44 |
| Week 48 | -4.5 ± 0.40 | -5.2 ± 0.43 | -4.3 ± 0.42 | -4.9 ± 0.48 | -4.9 ± 0.44 |
Normal Improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D. Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 31 | 29 | 28 | 25 | 24 |
| Week 48 | 34 | 34 | 29 | 22 | 25 |
Enhanced improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D and no worsening between consecutive visits from baseline up to the considered visit Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 7 | 16 | 11 | 6 | 13 |
| Week 48 | 5 | 10 | 7 | 6 | 7 |
The British Isles Lupus Assessment Group 2004 (BILAG-2004) is a comprehensive composite clinical index that has been developed based on the principle of a physician's intention to treat using a nominal consensus approach. In the index, the nine systems (not organs) considered are: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, renal, ophthalmic and hematological. Disease activity in each of the nine systems is categorized into five levels: grades A (= severe disease activity requiring systemic high dose oral corticosteroids, i.v. pulse corticosteroids, etc.) to E (= system never involved). BILAG total score is derived by assigning the following value to each grade and summing the sores over all organ systems: A = 12, B = 8, C = 1, D/E = 0. The total score ranges from 0-108, with 108 representing high disease activity in all 9 systems requiring high doses of corticosteroids, starting/increasing immunosuppressive drugs, etc.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 17.4 ± 0.78 | 17.9 ± 0.69 | 15.2 ± 0.68 | 17.4 ± 0.71 | 17.3 ± 0.82 |
| Week 24 | 6.8 ± 0.78 | 5.7 ± 0.79 | 7.0 ± 0.76 | 7.2 ± 0.94 | 7.4 ± 0.84 |
| Week 48 | 6.0 ± 0.73 | 4.0 ± 0.72 | 5.2 ± 0.74 | 6.0 ± 0.92 | 6.2 ± 0.91 |
An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D. Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 25 | 24 | 18 | 21 | 25 |
| Week 48 | 26 | 27 | 18 | 18 | 22 |
An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D. Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 41 | 39 | 36 | 36 | 33 |
| Week 48 | 40 | 38 | 35 | 33 | 31 |
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 15 | 24 | 19 | 16 | 16 |
| Week 48 | 20 | 27 | 23 | 16 | 19 |
The physician makes a mark between 0 ("no disease") and 100 mm ("severe disease") on the visual analogue scale (VAS) to indicate disease activity (independent of the subject's self-assessment). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline PGA score and geographic region as covariates. A negative change from baseline reflects an improvement.
| score on a scale | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -25.2 ± 2.03 | -28.4 ± 2.09 | -26.2 ± 2.04 | -23.5 ± 2.16 | -22.7 ± 2.08 |
| Week 48 | -28.3 ± 1.73 | -32.9 ± 1.82 | -30.2 ± 1.82 | -30.1 ± 2.00 | -30.5 ± 1.87 |
The subject makes a mark between 0 ("very good") and 100 mm ("very bad") on the VAS to indicate how the subject is doing, while considering all the ways SLE affects him/her. Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline Patient's Global Assessment and geographic region as covariates. A negative change from baseline reflects an improvement.
| score on a scale | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -12.4 ± 2.87 | -13.5 ± 2.96 | -14.9 ± 2.87 | -20.1 ± 3.05 | -16.0 ± 2.98 |
| Week 48 | -15.1 ± 2.70 | -21.5 ± 2.87 | -22.1 ± 2.82 | -27.2 ± 3.12 | -25.9 ± 2.94 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline proteinuria and geographic region as covariates
| g/mol | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 6.17 ± 3.730 | 1.77 ± 3.847 | 1.03 ± 3.735 | -3.02 ± 3.876 | 0.16 ± 3.962 |
| Week 48 | 4.89 ± 5.732 | 3.83 ± 6.152 | -1.62 ± 5.761 | -0.49 ± 6.582 | -1.21 ± 6.191 |
Efficacy Laboratory Parameters (Urinalysis) - Active Urine Sediment Number of subjects who were urine sediment negative at Baseline, but positive at Week 24 and Week 48, respectively.
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 1 | 0 | 0 | 0 | 0 |
| Week 48 | 0 | 0 | 0 | 0 | 0 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline serum creatinine and geographic region as covariates
| umol/L | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -1.25 ± 2.172 | -3.29 ± 2.237 | -1.50 ± 2.182 | -3.98 ± 2.309 | -0.86 ± 2.276 |
| Week 48 | 1.19 ± 2.016 | -1.87 ± 2.152 | -6.26 ± 2.085 | -4.04 ± 2.359 | -1.24 ± 2.199 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline eGFR and geographic region as covariates
| mL/min/1.73m2 | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -1.63 ± 2.869 | 4.83 ± 2.931 | -1.72 ± 2.854 | -0.90 ± 3.044 | -8.91 ± 3.014 |
| Week 48 | -6.00 ± 3.052 | 2.47 ± 3.231 | 4.66 ± 3.125 | -1.47 ± 3.562 | -8.08 ± 3.326 |
Defined as non-protocol allowed increase in steroid dose, start i.v. or i.m. steroids, or start or increase of immunosuppressant
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline to Week 24 | 2 | 0 | 4 | 2 | 3 |
| Baseline to Week 48 | 5 | 1 | 9 | 6 | 6 |
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline to Week 24 | 8 | 6 | 6 | 7 | 6 |
| Baseline to Week 48 | 8 | 6 | 10 | 9 | 9 |
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline to Week 24 | 1 | 0 | 2 | 2 | 1 |
| Baseline to Week 48 | 4 | 0 | 4 | 4 | 2 |
Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline prednisone equivalent total daily dose and geographic region as covariates
| percentage | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 3.87 ± 2.781 | -0.80 ± 2.922 | 0.25 ± 2.689 | -1.40 ± 2.940 | -3.46 ± 2.831 |
| Week 48 | 6.93 ± 5.047 | -3.22 ± 5.397 | -1.03 ± 5.050 | -2.32 ± 5.758 | -1.73 ± 5.521 |
Number and percentage of subjects whose prednisone equivalent dose was \>7.5 mg/day at baseline and reduced to ≤7.5 mg/day during Weeks 40-48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare after the first prednisone equivalent dose decrease.
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| BILAG-2004-defined Flare | 3 | 2 | 5 | 1 | 3 |
| mSFI-defined Flare | 3 | 2 | 4 | 1 | 4 |
Number and percentage of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| BILAG-2004-defined Flare | 0 | 0 | 1 | 1 | 0 |
| mSFI-defined Flare | 0 | 0 | 2 | 1 | 0 |
The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 4.71 ± 1.241 | 4.56 ± 1.286 | 6.77 ± 1.242 | 4.67 ± 1.321 | 5.01 ± 1.292 |
| Week 48 | 3.73 ± 1.414 | 6.97 ± 1.510 | 8.67 ± 1.460 | 8.62 ± 1.633 | 8.85 ± 1.535 |
The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | 0.08 ± 0.703 | -0.99 ± 0.724 | -0.56 ± 0.703 | 0.45 ± 0.749 | -1.18 ± 0.732 |
| Week 48 | 1.50 ± 0.716 | -0.58 ± 0.756 | -0.07 ± 0.737 | -1.07 ± 0.827 | -2.02 ± 0.777 |
Twenty-eight joints are assessed for swollenness (a score of 1 for a joint denotes a presence of swollenness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are swollen). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SJC28 Score and geographic region as covariates. A negative change denotes an improvement.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -4.8 ± 0.31 | -5.0 ± 0.32 | -4.9 ± 0.31 | -4.8 ± 0.33 | -4.5 ± 0.32 |
| Week 48 | -5.0 ± 0.28 | -5.4 ± 0.30 | -4.7 ± 0.29 | -5.1 ± 0.32 | -4.5 ± 0.30 |
Twenty-eight joints are assessed for tenderness (a score of 1 for a joint denotes a presence of tenderness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are tender). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline TJC28 Score and geographic region as covariates. A negative change denotes and improvement.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 24 | -6.8 ± 0.49 | -6.8 ± 0.50 | -6.4 ± 0.49 | -5.8 ± 0.52 | -5.5 ± 0.50 |
| Week 48 | -6.6 ± 0.43 | -7.4 ± 0.46 | -6.4 ± 0.45 | -6.6 ± 0.50 | -6.5 ± 0.47 |
CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (erythema: 0=absent, 1=pink, 2=red, 3=dark red; scale: 0=absent, 1=scale, 2=verrucous/hypertrophic). Mucous membrane involvement and acute hair loss are scored based on the presence (=1) or absence (=0). Nonscarring alopecia is scored as 0=absent, 1=diffuse/non-inflammatory, 2=focal or patchy in 1 quadrant, 3=focal or patchy in \>1 quadrant. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Activity Score and geographic region as covariates. Negative change = improvement
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 12 | -2.4 ± 0.53 | -1.9 ± 0.57 | -1.4 ± 0.65 | -1.6 ± 0.63 | -1.3 ± 0.57 |
| Week 24 | -1.1 ± 0.53 | -2.1 ± 0.60 | -1.6 ± 0.66 | -1.3 ± 0.65 | -1.8 ± 0.57 |
| Week 48 | -1.3 ± 0.59 | -3.0 ± 0.70 | -2.5 ± 0.73 | -2.1 ± 0.80 | -3.0 ± 0.64 |
CLASI Damage is scored based on dyspigmentation and scarring. Evaluation of dyspigmentation and scarring is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (dyspigmentation: 0=absent, 1=present; scarring: 0=absent, 1=scarring, 2=severely atrophic scarring or panniculitis). Subjects are also asked whether dyspigmentation due to SLE lesions usually remains visible for \>12 months, which is considered permanent and results in doubling of the dyspigmentation score. Scarring alopecia is scored as follows: 0=absent, 3=1 quadrant, 4=2 quadrants, 5=3 quadrants, 6=affects the whole skull. Total score ranges from 0-56, with higher scores indicating more damaged skin. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Damage Score and geographic region as covariates. Negative change = improvement.
| score | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Week 12 | 0.1 ± 0.49 | 0.1 ± 0.47 | -0.1 ± 0.59 | -0.3 ± 0.52 | -0.4 ± 0.52 |
| Week 24 | 0.4 ± 0.61 | -0.4 ± 0.61 | -0.4 ± 0.73 | 0.3 ± 0.67 | -0.1 ± 0.66 |
| Week 48 | 0.0 ± 0.57 | -0.1 ± 0.60 | -0.3 ± 0.68 | 0.4 ± 0.68 | -0.7 ± 0.63 |
| µg/mL | ALX-0061 75 mg 4qw | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|
| Week 24 | 0.118 ± 2.29 | 2.05 ± 3.89 | 18.1 ± 1.60 | 30.7 ± 1.62 |
| Week 48 | 0.155 ± 3.28 | 2.17 ± 3.45 | 17.9 ± 1.71 | 36.1 ± 1.46 |
| ng/mL | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 42.22 ± 2.496 | 37.63 ± 1.933 | 38.10 ± 1.895 | 42.14 ± 3.366 | 36.92 ± 1.810 |
| Week 24 | 39.70 ± 1.934 | 198.26 ± 18.856 | 603.51 ± 31.678 | 668.57 ± 25.568 | 634.49 ± 23.638 |
| Week 48 | 39.41 ± 2.270 | 224.66 ± 25.515 | 610.86 ± 29.445 | 650.73 ± 38.516 | 659.79 ± 32.862 |
| nmol/L | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 43.58 ± 9.527 | 49.05 ± 12.924 | 38.89 ± 8.394 | 66.32 ± 17.221 | 32.23 ± 4.957 |
| Week 24 | 59.43 ± 11.277 | 47.22 ± 9.607 | 26.08 ± 9.995 | 3.83 ± 0.668 | 3.20 ± 0.357 |
| Week 48 | 30.70 ± 4.709 | 37.65 ± 8.647 | 23.20 ± 6.705 | 4.41 ± 0.988 | 4.02 ± 0.962 |
| g/L | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 3.2 ± 0.09 | 3.2 ± 0.08 | 3.2 ± 0.09 | 3.2 ± 0.10 | 3.1 ± 0.09 |
| Week 24 | 3.3 ± 0.08 | 3.3 ± 0.10 | 2.3 ± 0.12 | 1.9 ± 0.05 | 1.9 ± 0.05 |
| Week 48 | 3.3 ± 0.09 | 3.3 ± 0.12 | 2.3 ± 0.11 | 1.9 ± 0.06 | 1.9 ± 0.05 |
| IU/mL | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 132.90 ± 54.467 | 145.87 ± 113.907 | 52.88 ± 17.283 | 68.92 ± 23.226 | 73.34 ± 25.940 |
| Week 24 | 81.36 ± 30.376 | 68.27 ± 35.053 | 46.99 ± 33.534 | 14.98 ± 4.499 | 23.25 ± 6.417 |
| Week 48 | 81.80 ± 24.143 | 59.48 ± 32.190 | 74.21 ± 48.030 | 9.13 ± 2.108 | 15.53 ± 6.069 |
| mg/dL | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 102.3 ± 3.82 | 100.2 ± 4.12 | 101.9 ± 3.79 | 105.8 ± 4.38 | 98.6 ± 3.98 |
| Week 24 | 101.7 ± 4.30 | 95.7 ± 3.81 | 82.0 ± 3.68 | 75.3 ± 2.90 | 71.8 ± 2.82 |
| Week 48 | 95.8 ± 4.25 | 93.2 ± 4.20 | 79.0 ± 3.25 | 83.2 ± 3.18 | 72.3 ± 2.61 |
| mg/dL | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 17.3 ± 1.08 | 17.8 ± 1.07 | 15.9 ± 0.96 | 18.7 ± 1.19 | 16.3 ± 1.04 |
| Week 24 | 17.5 ± 1.09 | 17.4 ± 1.10 | 10.6 ± 0.85 | 8.7 ± 0.40 | 7.9 ± 0.37 |
| Week 48 | 16.3 ± 1.15 | 17.3 ± 1.27 | 10.5 ± 0.84 | 9.8 ± 0.89 | 8.1 ± 0.41 |
| unit(s) | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Baseline | 101.1 ± 7.46 | 109.6 ± 8.83 | 98.9 ± 6.95 | 103.0 ± 7.47 | 82.4 ± 7.09 |
| Week 24 | 95.8 ± 7.94 | 107.0 ± 7.08 | 73.6 ± 6.94 | 56.7 ± 4.91 | 41.1 ± 3.63 |
| Week 48 | 102.2 ± 8.38 | 113.1 ± 8.63 | 73.5 ± 8.26 | 68.4 ± 6.95 | 41.9 ± 3.32 |
| Participants | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| Number and Percentage of Subjects Who Were Treatment-emergent (TE) Anti-drug Antibody (ADA) Positive | 32 | 16 | 18 | 31 | 38 |
Collected over From time of first study drug administration until the subject's study completion/discontinuation date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/62 (0%) | 7/62 (11.3%) | 40/62 (64.5%) |
| ALX-0061 75 mg q4w | 0/64 (0%) | 2/64 (3.1%) | 40/64 (62.5%) |
| ALX-0061 150 mg q4w | 0/62 (0%) | 4/62 (6.5%) | 31/62 (50%) |
| ALX-0061 150 mg q2w | 2/62 (3.2%) | 5/62 (8.1%) | 47/62 (75.8%) |
| ALX-0061 225 mg q2w | 0/62 (0%) | 5/62 (8.1%) | 44/62 (71%) |
| Event | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/62 | 0/64 | 1/62 | 0/62 | 2/62 |
| PneumoniaInfections and infestations | 2/62 | 0/64 | 0/62 | 1/62 | 0/62 |
| SinusitisInfections and infestations | 1/62 | 0/64 | 1/62 | 0/62 | 0/62 |
| Cytomegalovirus infectionInfections and infestations | 1/62 | 0/64 | 0/62 | 0/62 | 0/62 |
| ErysipelasInfections and infestations | 0/62 | 0/64 | 1/62 | 0/62 | 0/62 |
| Peritonsillar abscessInfections and infestations | 0/62 | 0/64 | 0/62 | 1/62 | 0/62 |
| Pulmonary tuberculomaInfections and infestations | 0/62 | 0/64 | 0/62 | 1/62 | 0/62 |
| Subcutaneous abscessInfections and infestations | 0/62 | 0/64 | 1/62 | 0/62 | 0/62 |
| Tuberculous pleurisyInfections and infestations | 0/62 | 0/64 | 0/62 | 1/62 | 0/62 |
| Ligament ruptureInjury, poisoning and procedural complications | 1/62 | 0/64 | 0/62 | 0/62 | 0/62 |
| Event | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 13/62 | 4/64 | 3/62 | 3/62 | 10/62 |
| Urinary tract infectionInfections and infestations | 8/62 | 5/64 | 7/62 | 3/62 | 8/62 |
| NasopharyngitisInfections and infestations | 6/62 | 6/64 | 5/62 | 2/62 | 1/62 |
| DiarrhoeaGastrointestinal disorders | 6/62 | 1/64 | 0/62 | 1/62 | 2/62 |
| NeutropeniaBlood and lymphatic system disorders | 2/62 | 3/64 | 3/62 | 5/62 | 6/62 |
| Hepatic enzyme increasedInvestigations | 0/62 | 0/64 | 1/62 | 6/62 | 0/62 |
| Upper respiratory tract infectionInfections and infestations | 5/62 | 5/64 | 5/62 | 5/62 | 3/62 |
| Injection site erythemaGeneral disorders | 0/62 | 2/64 | 2/62 | 5/62 | 5/62 |
| BronchitisInfections and infestations | 2/62 | 2/64 | 4/62 | 2/62 | 1/62 |
| SinusitisInfections and infestations | 2/62 | 3/64 | 0/62 | 4/62 | 1/62 |
| Age, Categorical(Participants) | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 62 | 64 | 62 | 62 | 62 | 312 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w | Total |
|---|---|---|---|---|---|---|
| Mean | 42.3 ± 10.11 | 42.0 ± 11.00 | 41.8 ± 10.79 | 39.2 ± 11.58 | 42.0 ± 10.44 | 41.4 ± 10.79 |
| Sex: Female, Male(Participants) | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w | Total |
|---|---|---|---|---|---|---|
| Female | 60 | 61 | 61 | 61 | 57 | 300 |
| Male | 2 | 3 | 1 | 1 | 5 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 12 | 17 | 11 | 13 | 66 |
| Not Hispanic or Latino | 49 | 52 | 45 | 51 | 49 | 246 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | ALX-0061 75 mg q4w | ALX-0061 150 mg q4w | ALX-0061 150 mg q2w | ALX-0061 225 mg q2w | Total |
|---|---|---|---|---|---|---|
| Argentina | 4 | 4 | 3 | 3 | 4 | 18 |
| Hungary | 2 | 4 | 2 | 2 | 4 | 14 |
| United States | 10 | 11 | 10 | 11 | 10 | 52 |
| Czechia | 2 | 1 | 0 | 0 | 3 | 6 |
| Philippines | 1 | 3 | 4 | 3 | 2 | 13 |
| Ukraine | 5 | 6 | 7 | 8 | 7 | 33 |
| Portugal | 2 | 2 | 0 | 1 | 1 | 6 |
| Russia | 3 | 6 | 5 | 8 | 6 | 28 |
| Spain | 3 | 2 | 2 | 1 | 0 | 8 |
| South Korea | 1 | 1 | 0 | 2 | 1 | 5 |
| Taiwan | 3 | 1 | 1 | 0 | 2 | 7 |
| Poland | 4 | 5 | 3 | 6 | 5 | 23 |
| Mexico | 5 | 6 | 5 | 5 | 5 | 26 |
| Chile | 0 | 1 | 1 | 0 | 0 | 2 |
| Serbia | 14 | 11 | 17 | 11 | 10 | 63 |
| Peru | 2 | 0 | 2 | 1 | 1 | 6 |
| Germany | 1 | 0 | 0 | 0 | 1 | 2 |
Showing the first 100 of 118 sites across 17 countries.
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic→
Ablynx, a Sanofi company